



THRIVE

AN ANNUAL COMPETITIVE
SEED GRANT PROGRAM

WHY THRIVE MATTERS

Relatively few grants support foundational studies aimed at understanding the unintended biological consequences of treatments—work that is essential to preventing or reducing the harmful impacts of therapy. THRIVE addresses this funding gap by supporting novel, translational research focused on quality of life.

Many THRIVE-funded projects are not yet far enough along for traditional funding sources, but they are critical to advancing survivorship science. THRIVE seed grants enable investigators to test initial hypotheses, generate preliminary data, and demonstrate impact—strengthening future funding applications and laying the groundwork for next-generation cancer treatments.

RESEARCH FOCUS

THRIVE-funded research advances:

- Fundamental understanding of toxicity associated with cancer drugs and therapies
- Identification and translation of key biomarkers of toxicity
- Development of predictive models (in vivo, in vitro, and in silico) in pediatric and adult populations
- Evaluation of protective co-therapies and modified exposure protocols
- Discovery of novel protective therapies and dosing strategies

Thrive awards have focused on a range of toxicities including:

- Cardiotoxicity
- Gastrointestinal toxicity
- Kidney / renal toxicity
- Neurocognitive toxicity
- Reproductive toxicity

IMPACT AT A GLANCE

THRIVE-supported research has led to:

\$6 MILLION+ in follow-on funding for awardees, a **~400%** return on investment.

10+ Peer-reviewed publications

30+ presentations

2 patents

New interdisciplinary collaborations across cardio-oncology, immunology, and survivorship science.

INVESTIGATORS

Think your project may be a good fit? Go to hesithrive.org/guidelines or contact research@hesithrive.org for more information on applying.

HESI THRIVE

Improving Quality of Life After Cancer Treatment

THE NEED

Cancer therapies are increasingly effective and lifesaving, enabling millions of patients to survive cancer—but too many patients and survivors experience treatment-related toxicities that can persist long after therapy ends and significantly impact quality of life and long-term health outcomes. There is a real and growing need to support research that is aimed at addressing the harms and adverse effects of treatments so that patients don't just survive but thrive.

OUR MISSION

HESI THRIVE seeks to make patient quality of life an active research priority and advance research to predict, prevent, reduce and mitigate treatment-related toxicities.

WHAT THRIVE DOES

THRIVE provides competitive seed funding to catalyze innovative translational research and technology-based solutions focused on treatment-related toxicities. The program supports “bench to bedside” investigations by teams comprised of both scientific and clinical disciplines.

In addition to funding, THRIVE connects investigators to interdisciplinary scientific networks that enhance collaboration, visibility, and translational potential.

TO DATE

28 THRIVE-funded research projects

\$1.4 MILLION in total funding to date

There are
53 MILLION
cancer survivors
worldwide

The five-year
survival rate for all
cancers is now
70%

60%
of cancer survivors
live with adverse
treatment effects

“The paradigm for what defines a successful cancer cure must be expanded to go beyond just 5-year, cancer-event-free survival. It must balance oncologic efficacy with the toxicity and late effects of treatment as measured by a quality of life over a lifespan.”

*Steven Lipshultz,
MD, FAAP, FAHA*

